A 62-year-old man with type 2 diabetes for 8 years, obesity, and established coronary artery disease has an HbA1c of 7.9 percent despite maximised metformin therapy. eGFR is 65 mL/min/1.73 m2 and albumin-to-creatinine ratio is 5 mg/mmol. According to Diabetes Canada pharmacologic guidance, which agent class is preferred as the next add-on therapy to improve both glycaemic control and cardiovascular outcomes?